Top Biomed Stock Signal: ASND
Report Date: 03-17-2024
Symbol: ASND - Ascendis Pharma A/S
Sector:
Industry:
Top Biomed Stock Signal: ASND
Ascendis Pharma A/S (ASND)
Tuborg Boulevard 5
Hellerup, 2900
Phone: 4570222244
Website: http://www.ascendispharma.com
CEO: Mr. Jan Moeller Mikkelsen
NASDAQ, Nasdaq Global Select
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.